产品说明
包装
100, 500 mg in poly bottle
生化/生理作用
α-肾上腺素受体拮抗剂;外周血管舒张剂。
特点和优势
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
线性分子式 | C17H19N3O · CH3SO3H |
分子量 | 377.46 |
EC 号 | 200-604-6 |
MDL编号 | MFCD00134201 |
PubChem化学物质编号 | 24277798 |
NACRES | NA.77 |
产品性质
质量水平 | 200 |
测定 | ≥98% (TLC) |
形式 | powder |
颜色 | white to off-white |
mp | 180-182 ℃ (lit.) |
溶解性 | ethanol: 26 mg/mL H2O: 50 mg/mL |
创始人 | Novartis |
SMILES string | CS(O)(=O)=O.Cc1ccc(cc1)N(CC2=NCCN2)c3cccc(O)c3 |
InChI | 1S/C17H19N3O.CH4O3S/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15;1-5(2,3)4/h2-8,11,21H,9-10,12H2,1H3,(H,18,19);1H3,(H,2,3,4) |
InChI key | OGIYDFVHFQEFKQ-UHFFFAOYSA-N |
Gene Information | human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152) |
安全信息
象形图 | |
警示用语: | Warning |
危险声明 | H302 - H315 - H319 - H335 |
预防措施声明 | P261 - P264 - P270 - P301 + P312 - P302 + P352 - P305 + P351 + P338 |
危险分类 | Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
靶器官 | Respiratory system |
储存分类代码 | 11 - Combustible Solids |
WGK | WGK 3 |
个人防护装备 | dust mask type N95 (US), Eyeshields, Gloves |